Aurobindo Pharma rises on receiving USFDA nod for Tamsulosin HCL Capsules and Pediatric

06 May 2013 Evaluate

Aurobindo Pharma is currently trading at Rs. 198.00, up by 1.45 points or 0.74% from its previous closing of Rs. 196.55 on the BSE.

The scrip opened at Rs. 198.50 and has touched a high and low of Rs. 199.25 and Rs. 197.80 respectively. So far 34,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.90 on 03-Jan-2013 and a 52 week low of Rs. 99.65 on 10-Aug-2012.

Last one week high and low of the scrip stood at Rs. 202.35 and Rs. 187.00 respectively. The current market cap of the company is Rs. 5,765.00 crore.

The promoters holding in the company stood at 54.84% while Institutions and Non-Institutions held 31.87% and 13.29% respectively.

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Tamsulosin Hydrochloride Capsules USP 0.4mg (ANDA 202433) and Clindamycin Palmitate Hydrochloride for Oral Solution USP (Pediatric), 75mg (base)/5mL (ANDA 202409). The products will be launched soon.

Tamsulosin Hydrochloride Capsules USP 0.4mg is the generic equivalent of Boehringer Ingelheim Pharmaceuticals’ Flomax Capsules, 0.4mg and is indicated for the treatment of symptoms of an enlarged prostate (Benign Prostatic Hyperplasia - BPH) in men. The market size of the product is estimated to be $244 million for the twelve months ending September 2012 according to IMS.

Clindamycin Palmitate Hydrochloride for Oral Solution USP (Pediatric), 75mg (base)/5mL is the generic equivalent of Pharmacia & Upjohn’s Cleocin Pediatric for oral solution, 75mg (base)/5mL and is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria in infants. The market size of the product is estimated to be $57 million for the twelve months ending September 2012 according to IMS. Aurobindo now has a total of 190 ANDA approvals (163 Final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1172.50 1.10 (0.09%)
11-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.90
Dr. Reddys Lab 1272.95
Cipla 1512.10
Zydus Lifesciences 922.45
Lupin 2080.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×